Circle Pharma’s work with Pfizer yields new macrocyclic peptides

By Michael Fitzhugh
Staff Writer

Circle Pharma Inc., of South San Francisco, said its first collaboration with Pfizer Inc. has led to the identification of a series of bioavailable macrocyclic peptides capable of acting as potent and cell-permeable modulators of CXCR7…

Read article at BioWorld

Starting up and spinning out: The changing nature of partnerships between pharma and academia
Peptide Therapeutics Near the Sweetest Spots